SureTrader Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, TPX, Peacefulwendy, The Promised Land, BioNewton, $Pistol Pete$
Search This Board:
Last Post: 7/29/2016 9:57:54 AM - Followers: 603 - Board type: Free - Posts Today: 16

Welcome to PharmaCyte BioTech
All Video About PharmaCyte Biotech heads into the final preparations for its Phase 2b clinical trial in advanced pancreatic cancer, the company hosted a medical and scientific discussion of our therapy for advanced pancreatic cancer among top oncologist investigators who have expressed interest in PharmaCyte’s technology and participation in the Phase 2b clinical trial. Below you will find the 5 presentations that were delivered to those invited oncologists. After Dr. Manuel Hidalgo, a member of PharmaCyte's medical and scientific advisory board, completed his presentation of the design of the upcoming Phase 2b clinical trial, an hour-long discussion took place between those invited oncologists and those representing PharmaCyte Biotech; Dr. Matthias Löhr, Dr. Manuel Hidalgo, Prof. Dr. Walter H. Günzburg, and Dr. Brian Salmons.



$PMCB Enjoy Corporate Video





$PMCB Enjoy Discovery Channel Video






$PMCB Enjoy Another Great Video YouTube TGen Leads the Way in Early Detection of Cancer. Dr. Von Hoff will lead $PMCB into FDA Fast Track Approval







FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe

Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.


Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development


Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).

Dr. Manuel Hidalgo, Scientific Advisory Board:

Manual Hidalgo is the Vice Director of Translational Research, Clinical Research Program Director and Head of Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) and Director at the Centro Integral Oncologico Clara Campal (CIOCC). In addition he is a professor of Oncology at the University CEU San Pablo. Dr. Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialized in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programs. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the Pancreatic Cancer Research Team (PCRT) - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. - See more at:



Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report


•The Board Monitor and The Board Assistants herewith, are not licensed brokers and
assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.

•We do NOT recommend that anyone buy or sell any securities posted herewith.
Any trade entered into risks the possibility of losing the funds invested.
•There are no guarantees when buying or selling any security.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PMCB News: PharmaCyte Biotech Releases Shareholder Call Playback Information 09:00 AM
PMCB News: PharmaCyte Biotech Shareholder Call Update 07/25/2016 09:00:00 AM
PMCB News: As Diabetes Becomes Global Epidemic, PharmaCyte Biotech's Insulin Producing Cells Receive 20 Years of Protection 07/19/2016 09:00:00 AM
PMCB News: Extraction Technology Becoming Paramount In Cannabis Industry as Consumers Gravitate Towards Concentrates And Higher Quality of 07/19/2016 08:30:00 AM
PMCB News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 07/14/2016 04:02:03 PM
News News Alert: PharmaCyte Biotech Releases Shareholder Call Playback Information 07/29/2016 09:00:00 AM
#50322  Sticky Note $PMCB Extraction Technology Becoming Paramount in Cannab $Pistol Pete$ 07/20/16 03:55:24 AM
#50053  Sticky Note PMCB PharmaCyte Biotech Receives Patent Protection of the TPX 07/14/16 09:08:15 AM
#49713  Sticky Note needs some fast action/ Looking for a Comeback mick 06/28/16 01:09:36 AM
#49622  Sticky Note PharmaCyte Biotech Releases Medical and Scientific Discussion from Peacefulwendy 06/23/16 10:12:56 AM
#49249  Sticky Note PMCB - Clinical Trial Costs - Not as BioNewton 06/03/16 09:30:47 PM
#50797   PMCB PharmaCyte Biotech Releases Shareholder Call Playback Information TPX 07/29/16 09:57:54 AM
#50796   Does keep up the fantastic work mean have A_realist 07/29/16 09:47:10 AM
#50795   Check another 2016 milestone from the list rudygerner 07/29/16 09:37:10 AM
#50794   $PMCB Daily & Weekly Chart http://stock $Pistol Pete$ 07/29/16 09:34:51 AM
#50793   Just be patience and waiting to read the $Pistol Pete$ 07/29/16 09:25:37 AM
#50792   While I'm disappointed that the schedule (pre ind rcstock 07/29/16 09:20:38 AM
#50791   $PMCB PharmaCyte Biotech Releases Shareholder Call Playback Information http:// $Pistol Pete$ 07/29/16 09:17:03 AM
#50790   Asia markets also being explored... TheBestInvest 07/29/16 09:14:01 AM
#50789   Yeah...yeah...yeah...oh boy...longs will just have to buy more...pancreatic efood125 07/29/16 08:52:26 AM
#50788   $PMCB PharmaCyte Biotech - Diabetes Treatment Program Th $Pistol Pete$ 07/29/16 01:31:08 AM
#50787   Nothing said about pmcb except their name listed frosr6 07/29/16 01:23:32 AM
#50786   Hey ya think pmcb will report $75m? Considering frosr6 07/29/16 01:16:55 AM
#50785   Pmcb dropping to .03's soon. Boy oh frosr6 07/29/16 01:12:19 AM
#50784   It's possible after today's pathetic CC that delusional frosr6 07/29/16 01:10:23 AM
#50783   Well said. Todays pathetic CC would have frosr6 07/29/16 01:03:21 AM
#50782   $PMCB What Are Clinical Stage Biotech Stocks? http $Pistol Pete$ 07/29/16 12:53:43 AM
#50781   And the name of the mysterious Bio company? BioNewton 07/28/16 11:05:44 PM
#50780   $PMCB Research report explores the pancreatic cancer pipeline $Pistol Pete$ 07/28/16 10:32:09 PM
#50778 see it your way and I see efood125 07/28/16 10:13:43 PM
#50777   $PMCB 10-K will be out tomorrow and when $Pistol Pete$ 07/28/16 09:52:47 PM
#50776   $PMCB We are still on track with what $Pistol Pete$ 07/28/16 09:46:32 PM
#50775   efood, of course words matter but only in iwitness4jc 07/28/16 09:45:03 PM
#50774   Not to mention there's another bio on the Hotelier51 07/28/16 09:44:30 PM
#50773   Pmcb will never go to trials. Never was. frosr6 07/28/16 09:42:32 PM
#50772   Great point efood. I forgot he said that. Peacefulwendy 07/28/16 09:41:16 PM
#50771   I've maintained that all along. Imo, PharmaCyte will rudygerner 07/28/16 09:39:53 PM
#50770   Me too, Pete. I will continue to Peacefulwendy 07/28/16 09:37:00 PM
#50769   I liked the CC today. I was lucky $Pistol Pete$ 07/28/16 09:34:09 PM
#50768   How long have they been doing this reengineering Peacefulwendy 07/28/16 09:28:18 PM
#50767   He clearly stated there have been companies showing TheBestInvest 07/28/16 09:14:39 PM
#50766   Thank you ;-) Go $PMCB $Pistol Pete$ 07/28/16 08:49:23 PM
#50765   He spoke with conviction. He brought up his byeandhold 07/28/16 08:12:06 PM
#50763   Yes. Better wording BioNewton 07/28/16 07:36:21 PM
#50762   I think he said slow the accumulation of efood_dude 07/28/16 07:34:21 PM
#50761 best friend is a wall street lawyer....words efood125 07/28/16 07:33:03 PM
#50760   And I liked the realization that failure is efood_dude 07/28/16 07:28:47 PM
#50759   Kept saying plan to release 10K tomorrow efood_dude 07/28/16 07:24:43 PM
#50758   Sounds like info on the joint venture will BioNewton 07/28/16 07:23:53 PM
#50757   Yes sir. That sums it up pretty BioNewton 07/28/16 07:23:05 PM
#50756   And what does this have to do with takeyouhigher 07/28/16 07:20:04 PM
#50755   Satisfied Points I gleaned: no immediate need for cash; byeandhold 07/28/16 07:16:49 PM
#50754   I believe you are parsing the statement way iwitness4jc 07/28/16 07:14:40 PM
#50753   Wrong....he said all necessary board spots were efood125 07/28/16 07:08:54 PM
#50752   e-food, the only thing I remember him saying iwitness4jc 07/28/16 07:06:09 PM
#50751   Wrong....cell in box can last over 2 years efood125 07/28/16 07:05:50 PM
#50750   Wrong....cell in box can last over 2 years efood125 07/28/16 07:05:48 PM
#50749   Can you show us where he said that please? BioNewton 07/28/16 07:02:05 PM
#50748   I learn something from the call,those waiting for thenewmixer 07/28/16 06:56:45 PM
#50747   Bio, I totally agree and am looking forward iwitness4jc 07/28/16 06:53:31 PM
#50746   There are other biotechs with advanced cell technologies takeyouhigher 07/28/16 06:47:25 PM